# ‚öîÔ∏è AYESHA'S CLINICAL TRIAL EXPLORER - DEMO SCRIPT ‚öîÔ∏è

**Purpose**: Show oncologist the complete Ayesha care plan system  
**Duration**: 5-7 minutes  
**Audience**: Oncologist, Clinical Team  
**Date**: January 13, 2025

---

## üéØ **DEMO OBJECTIVE**

**Show**: How the platform helps Ayesha (Stage IVB ovarian cancer) find the right clinical trials and get a complete care plan in minutes, not weeks.

**Key Messages**:
1. **Transparency**: Every recommendation has clear reasoning and confidence scores
2. **Speed**: Complete care plan in 3-5 minutes (vs 2-4 weeks manual research)
3. **Confidence**: Deterministic confidence gates (not black-box AI)
4. **Early Detection**: CA-125 monitoring catches resistance 3-6 weeks early

---

## üöÄ **SETUP (2 MINUTES)**

### **Step 1: Start Backend** (30 seconds)
```bash
cd oncology-coPilot/oncology-backend-minimal
uvicorn api.main:app --reload --host 0.0.0.0 --port 8000
```

**Expected Output**:
```
INFO:     Uvicorn running on http://0.0.0.0:8000
INFO:     Application startup complete.
```

**Verification**: Open `http://localhost:8000/api/ayesha/trials/health` in browser ‚Üí Should see JSON response

---

### **Step 2: Start Frontend** (30 seconds)
```bash
cd oncology-coPilot/oncology-frontend
npm run dev
```

**Expected Output**:
```
VITE v5.x.x ready in xxx ms
‚ûú  Local: http://localhost:5173/
```

**Verification**: Open `http://localhost:5173` in browser ‚Üí Should see app homepage

---

### **Step 3: Navigate to Ayesha's Page** (30 seconds)
1. Click "Ayesha Trials" in sidebar (or navigate to `/ayesha-trials`)
2. Page should load automatically with Ayesha's profile
3. Wait for API call to complete (loading spinner ‚Üí results)

---

## üé¨ **DEMO FLOW (5 MINUTES)**

### **Scene 1: Profile Summary** (30 seconds)

**What to Show**:
- **Patient**: Ayesha Kiani
- **Diagnosis**: Stage IVB Ovarian Cancer (High-Grade Serous)
- **CA-125**: 2,842 U/mL (EXTENSIVE disease burden)
- **Germline**: Negative (Ambry Genetics, June 2023)
- **Treatment Status**: First-line (treatment-naive)
- **Location**: NYC Metro

**What to Say**:
> "Ayesha is a 40-year-old woman with Stage IVB ovarian cancer. Her CA-125 is 2,842, indicating extensive disease. She's germline-negative, treatment-naive, and needs frontline therapy. Our system automatically generates a complete care plan in seconds."

---

### **Scene 2: SOC Recommendation** (1 minute)

**What to Show**:
- **Regimen**: Carboplatin + Paclitaxel + Bevacizumab
- **Confidence**: 95% (NCCN-aligned)
- **Rationale**: "NCCN first-line for Stage IVB HGSOC + bevacizumab for ascites/peritoneal disease"
- **Evidence**: GOG-218 (HR 0.72, p<0.001), ICON7
- **Detailed Dosing**: Calvert formula, premedication, infusion times
- **Monitoring Protocol**: Baseline labs, cycle labs, toxicity watch, RECIST 1.1

**What to Say**:
> "The system recommends standard-of-care: Carboplatin + Paclitaxel + Bevacizumab. This is 95% confidence, NCCN-aligned. Notice it includes Bevacizumab because Ayesha has ascites and peritoneal disease - the system automatically factors in these clinical details. The recommendation includes detailed dosing, monitoring protocols, and evidence citations."

**Key Point**: "This isn't just a drug list - it's a complete treatment plan with dosing, monitoring, and evidence."

---

### **Scene 3: CA-125 Intelligence** (1 minute)

**What to Show**:
- **Current Value**: 2,842 U/mL
- **Burden Class**: EXTENSIVE
- **Forecast**:
  - Cycle 3: Expect ‚â•70% drop ‚Üí <854 U/mL
  - Cycle 6: Expect ‚â•90% drop ‚Üí <284 U/mL
  - Target: <35 U/mL (complete response)
- **Resistance Signals**: ‚ö†Ô∏è Alert if on-therapy rise OR <50% drop by cycle 3
- **Monitoring Strategy**: Track every 3 weeks during chemo

**What to Say**:
> "The system analyzes CA-125 to predict response and detect resistance early. With a baseline of 2,842, we expect a 70% drop by cycle 3 if she's chemo-sensitive. If she doesn't hit that target, or if CA-125 rises on therapy, that's a resistance signal - and we catch it 3-6 weeks earlier than imaging would show progression."

**Key Point**: "Early resistance detection saves 3-6 weeks of ineffective therapy."

---

### **Scene 4: Top 10 Clinical Trials** (2 minutes)

**What to Show**:
- **Ranked List**: Top 10 trials sorted by match score
- **Match Score**: Bar chart showing 0.85-0.95 range
- **Reasoning Sections**:
  - ‚úÖ Why Eligible: Hard criteria (Stage IV, first-line, recruiting, NYC metro)
  - ‚úÖ Why Good Fit: Soft criteria (biomarkers, CA-125 tracking, etc.)
  - ‚ö†Ô∏è Conditional: What's required (ECOG status, organ function, etc.)
  - ‚ùå Red Flags: Exclusion criteria (if any)
- **Location Badges**: üìç NYC Metro for NY/NJ/CT sites
- **Confidence Gates**: Green checks for satisfied gates

**What to Say**:
> "The system found 10 frontline trials ranked by match score. Each trial has transparent reasoning - why Ayesha is eligible, why it's a good fit, what's conditional, and any red flags. Notice the confidence gates - these are deterministic, not black-box AI. We show exactly why each trial matches."

**Key Point**: "Transparency builds trust. Every recommendation has clear reasoning."

**If Trials Empty**:
> "If the trials list is empty, it means either AstraDB needs more seeding, or the hard filters are too restrictive. The system is working correctly - it's just that no trials match all criteria. We can adjust filters or seed more trials."

---

### **Scene 5: Eligibility Checklists** (30 seconds)

**What to Show**:
- **Hard Criteria**: All green checks (Stage IV ‚úÖ, First-line ‚úÖ, Recruiting ‚úÖ, NYC metro ‚úÖ)
- **Soft Criteria**: Some yellow warnings (ECOG unknown, organ function pending)
- **Confidence Gate**: 0.85-0.90 (based on hard/soft split)

**What to Say**:
> "Each trial has an eligibility checklist. Hard criteria must pass - Ayesha passes all of them. Soft criteria are warnings - some are unknown (ECOG status, organ function). The confidence gate reflects this - 0.85-0.90 means high confidence, but some soft criteria need verification."

---

### **Scene 6: NGS Fast-Track** (30 seconds)

**What to Show**:
- **Checklist**: 
  - ctDNA (7 days) - Unlocks WIWFM drug predictions
  - HRD testing (10 days) - Unlocks PARP eligibility
  - IHC (3 days) - Unlocks biomarker matching
- **Parallel Execution**: ~10 days total (not sequential)
- **Unlocked Capabilities**: WIWFM, biomarker matching, PARP eligibility

**What to Say**:
> "The system shows what NGS tests to order and how long they take. If we order all three in parallel, we get results in about 10 days. This unlocks personalized drug predictions, biomarker matching, and PARP eligibility - features that are grayed out until NGS completes."

**Key Point**: "The system guides you on what to order and why it matters."

---

### **Scene 7: Provenance & Transparency** (30 seconds)

**What to Show**:
- **Run ID**: Unique identifier for this analysis
- **Profile**: Baseline/Richer S/Fusion (which AI models used)
- **Confidence Gates**: Which gates were satisfied
- **Data Sources**: Where recommendations came from

**What to Say**:
> "Every analysis has complete provenance - run ID, which models were used, which confidence gates were satisfied, and where the data came from. This is audit-ready. You can reproduce any recommendation exactly."

**Key Point**: "Complete transparency and reproducibility."

---

## üí¨ **KEY TALKING POINTS**

### **1. Speed** (30 seconds)
> "This used to take 2-4 weeks of manual research. Now it's 3-5 minutes. Ayesha needs treatment in 2-4 weeks - we can't wait weeks for trial matching."

### **2. Transparency** (30 seconds)
> "Every recommendation has clear reasoning. We show why each trial matches, what's conditional, and what the confidence gates are. This isn't black-box AI - it's deterministic, auditable, and reproducible."

### **3. Early Detection** (30 seconds)
> "CA-125 monitoring catches resistance 3-6 weeks earlier than imaging. If Ayesha's CA-125 doesn't drop 70% by cycle 3, that's a resistance signal - and we can switch therapy before progression shows on CT scan."

### **4. Confidence Gates** (30 seconds)
> "Our confidence gates are deterministic. SOC recommendation is 95% because it's NCCN-aligned. Trial matches are 85-90% because hard criteria all pass and soft criteria are mostly known. This isn't AI guessing - it's transparent scoring."

### **5. Research Use Only** (15 seconds)
> "This is research-grade, not clinical decision-making. All outputs are clearly labeled RUO. The oncologist makes the final decision - we provide intelligence to inform that decision."

---

## üéØ **DEMO CHECKLIST**

**Before Demo**:
- [ ] Backend server running (port 8000)
- [ ] Frontend server running (port 5173)
- [ ] Browser open to `/ayesha-trials`
- [ ] API call succeeds (check network tab)
- [ ] All components render correctly

**During Demo**:
- [ ] Show profile summary
- [ ] Show SOC recommendation (emphasize Bevacizumab for ascites)
- [ ] Show CA-125 intelligence (emphasize early resistance detection)
- [ ] Show top 10 trials (emphasize transparent reasoning)
- [ ] Show eligibility checklists (emphasize hard/soft split)
- [ ] Show NGS fast-track (emphasize unlocked capabilities)
- [ ] Show provenance (emphasize transparency)

**After Demo**:
- [ ] Answer questions
- [ ] Show how to export (if implemented)
- [ ] Discuss next steps (NGS ordering, trial enrollment)

---

## ‚ö†Ô∏è **TROUBLESHOOTING**

### **Backend Won't Start**
- Check Python version: `python3 --version` (need 3.8+)
- Check dependencies: `pip install -r requirements.txt`
- Check port 8000 not in use: `lsof -i :8000`

### **Frontend Won't Start**
- Check Node version: `node --version` (need 16+)
- Check dependencies: `npm install`
- Check port 5173 not in use: `lsof -i :5173`

### **API Call Fails**
- Check backend is running: `curl http://localhost:8000/health`
- Check CORS: Backend should allow `http://localhost:5173`
- Check network tab: Look for 500 errors, check response body

### **Trials List Empty**
- **Expected**: If AstraDB not seeded or no matching trials
- **Not a Bug**: System is working correctly, just no matches
- **Solution**: Seed more frontline ovarian trials or adjust filters

### **SOC Missing Bevacizumab**
- Check request includes `has_ascites: true` and `has_peritoneal_disease: true`
- Check backend logic: Should add Bevacizumab if ascites/peritoneal disease

---

## üìä **DEMO METRICS**

**Time Breakdown**:
- Setup: 2 minutes
- Demo: 5-7 minutes
- Q&A: 3-5 minutes
- **Total**: 10-14 minutes

**Key Numbers to Mention**:
- **Speed**: 3-5 minutes (vs 2-4 weeks manual)
- **Confidence**: 85-95% (deterministic gates)
- **Early Detection**: 3-6 weeks (CA-125 vs imaging)
- **Transparency**: 100% (all reasoning visible)

---

## üé¨ **DEMO SCRIPT SUMMARY**

1. **Setup** (2 min): Start backend + frontend
2. **Profile** (30 sec): Show Ayesha's clinical profile
3. **SOC** (1 min): Show standard-of-care recommendation
4. **CA-125** (1 min): Show monitoring and early resistance detection
5. **Trials** (2 min): Show top 10 with transparent reasoning
6. **Eligibility** (30 sec): Show hard/soft criteria split
7. **NGS** (30 sec): Show fast-track checklist
8. **Provenance** (30 sec): Show transparency and auditability

**Total**: 5-7 minutes + Q&A

---

**Script Created**: January 13, 2025  
**Script Status**: ‚úÖ **COMPLETE** - Ready for demo


